Fjarde Ap-fonden’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.43M | Sell |
59,123
-8,500
| -13% | -$1.07M | 0.07% | 264 |
|
|
2025
Q1 | $7.48M | Buy |
67,623
+12,000
| +22% | +$1.33M | 0.09% | 214 |
|
|
2024
Q4 | $7.59M | Buy |
55,623
+2,300
| +4% | +$314K | 0.08% | 243 |
|
|
2024
Q3 | $6.14M | Buy |
+53,323
| New | +$6.14M | 0.06% | 301 |
|
|
2024
Q1 | $5.8M | Buy |
42,023
+3,500
| +9% | +$483K | 0.06% | 305 |
|
|
2023
Q4 | $5.08M | Sell |
38,523
-6,177
| -14% | -$814K | 0.06% | 322 |
|
|
2023
Q3 | $5.03M | Buy |
44,700
+7,800
| +21% | +$878K | 0.07% | 310 |
|
|
2023
Q2 | $3.48M | Buy |
36,900
+11,000
| +42% | +$1.04M | 0.04% | 407 |
|
|
2023
Q1 | $2.62M | Buy |
25,900
+4,100
| +19% | +$415K | 0.04% | 427 |
|
|
2022
Q4 | $2.6M | Sell |
21,800
-5,300
| -20% | -$633K | 0.04% | 432 |
|
|
2022
Q3 | $2.64M | Hold |
27,100
| – | – | 0.03% | 467 |
|
|
2022
Q2 | $2.64M | Sell |
27,100
-1,200
| -4% | -$117K | 0.03% | 467 |
|
|
2022
Q1 | $2.65M | Sell |
28,300
-7,600
| -21% | -$712K | 0.03% | 512 |
|
|
2021
Q4 | $3.06M | Buy |
35,900
+1,600
| +5% | +$136K | 0.03% | 500 |
|
|
2021
Q3 | $3.29M | Sell |
34,300
-2,800
| -8% | -$269K | 0.03% | 499 |
|
|
2021
Q2 | $3.61M | Buy |
37,100
+2,100
| +6% | +$204K | 0.03% | 488 |
|
|
2021
Q1 | $3.4M | Buy |
35,000
+800
| +2% | +$77.8K | 0.03% | 488 |
|
|
2020
Q4 | $3.28M | Buy |
34,200
+3,000
| +10% | +$288K | 0.03% | 487 |
|
|
2020
Q3 | $3M | Buy |
31,200
+2,700
| +9% | +$260K | 0.03% | 475 |
|
|
2020
Q2 | $3.48M | Sell |
28,500
-700
| -2% | -$85.4K | 0.04% | 410 |
|
|
2020
Q1 | $2.53M | Sell |
29,200
-500
| -2% | -$43.3K | 0.04% | 429 |
|
|
2019
Q4 | $3.19M | Buy |
+29,700
| New | +$3.19M | 0.04% | 477 |
|